ClinicalTrials.gg
CompletedNCT02224053Updated Jun 24, 2016Results posted

Drug-Drug Interaction Study With AZD9291 and Omeprazole in Healthy Volunteers

A Phase 1 interventional study of Pharmacokinetic sampling - AZD9291 and AZD9291 tablet dosing in Healthy Volunteer, sponsored by AstraZeneca. Completed at 2 sites in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-06-24.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
136
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

This is a Phase 1, open-label, 2-period fixed sequence design to evaluate the interaction of AZD9291 with omeprazole in approximately 50 healthy, adult male volunteers. Volunteers will receive Treatment A (AZD9291 and omeprazole) in Period 1 and Treatment B (AZD9291 only) in Period 2. The dose of AZD9291 in Period 1 and the dose of AZD9291 in Period 2 will be separated by a washout of at least 21 days (the washout will not be more than 5 weeks). The study will be performed at up to 2 sites in the USA and will assess the effect of omeprazole (proton pump inhibitor) on AZD9291 exposure

02

Conditions studied

  • Healthy Volunteer

Keywords

  • oncology, cancer, non small cell lung cancer, anticancer druge, omeprazole, healthy volunteer
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 136 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Eligibility criteria

For inclusion in the study volunteers must fulfil the following criteria.

  1. Provision of signed and dated prior to any study-specific procedures.
  2. Healthy male volunteers aged 18 to 55 years. (Healthy as determined by medical history, physical examination, laboratory parameters, , and eye examination performed before the first administration of product.)
  3. between 19 and 30 kg/m2, and body weight between 50 kg and 100 kg, inclusive.
  4. Veins suitable for cannulation or repeated venepuncture.
  5. Volunteers must be willing to use reliable methods of (condom and spermicide), even if their partners are , surgically sterile, or using an effective hormonal method of contraception or intrauterine coil. In addition, volunteers must agree to continue to take similar contraceptive precautions and avoid sperm donation for 6 months after the last administration of AZD9291.

Volunteers must not enter the study if any of the following exclusion criteria are fulfilled:

  1. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca and Quintiles staff).
  2. Previous enrollment in the present study.
  3. History of any disease or disorder which, in the opinion of the Investigator, may either put the healthy volunteer at risk because of participation in the study, or influence the results or the healthy volunteer's ability to participate in the study.
  4. History or presence of gastrointestinal, hepatic, or renal disease or surgical procedure or any other condition known to interfere with the absorption, distribution, metabolism, or excretion of drugs.
  5. Any clinically significant abnormalities in physical examination, vital signs (supine blood pressure >140 mmHg systolic, >90 mmHg diastolic, or pulse rate ≤35 or ≥100 beats per minute), or clinical laboratory assessment as judged by the Investigator.
  6. Acute illness, surgical procedures, or trauma from within 2 weeks before enrollment until first administration of investigational product (IP).
  7. Volunteers who have received live or in the 2 weeks prior to dosing.
  8. Volunteers with active or neoplastic disease in the previous 12 months.
  9. A suspected/manifested infection according to International Airline Transportation Association (IATA) Categories A and B infectious substances.
  10. Positive results on screening tests for serum surface antigen (HBsAg), antibody, or (HIV).
  11. Any clinically important abnormalities in rhythm, conduction, or morphology of resting ECG, as judged by the Investigator.
  12. Known or suspected history of significant drug abuse as judged by the Investigator.
  13. Positive screen for drugs of abuse or cotinine (nicotine level above 400 ng/mL) at screening or positive screen for alcohol, drugs of abuse, or cotinine on admission in Period 1 or Period 2.
  14. History of alcohol abuse or excessive intake of alcohol, defined as regular weekly intake of greater than 21 units of alcohol in men (Note: 1 unit=25 mL spirits, 125 mL wine, or 250 mL beer or lager).
  15. History of severe allergy/ or ongoing allergy/hypersensitivity, as judged by the Investigator, or history of hypersensitivity to AZD9291, its , or drugs with a similar chemical structure or class.
  16. History of hypersensitivity to omeprazole, its excipients, or drugs with a similar chemical structure or class.
  17. Use of any prescribed or nonprescribed medication, including drugs with hepatic enzyme-altering properties, such as St John's Wort, antacids, analgesics, herbal remedies, vitamins, and minerals during the 4 weeks (or longer depending on the medication's half-life) prior to the first administration of AZD9291 is not permitted. Occasional use of paracetamol (acetaminophen) and nonsteroidal nasal decongestant is permitted at the discretion of the Investigator.
  18. Any intake of grapefruit, grapefruit juice, Seville oranges, Seville orange marmalade, or other products containing grapefruit or Seville oranges within 7 days of the first administration of IP.
  19. Blood donation within 1 month of screening or any blood donation/blood loss greater than 500 mL during the 3 months prior to screening.
  20. Use of another new chemical entity (defined as a compound which has not been approved for marketing) or participation in any other clinical study (including methodology studies where no drugs were given) within 3 months of the first administration of IP in this study.
  21. Current smokers or those who have smoked or used nicotine products within the previous 3 months.
  22. Planned inpatient surgery, dental procedure, or hospitalisation during the study.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
136 participants (actual)

Study arms

  • Experimental
    AZD9291 and omeprazole

    Sequential treatments of AZD9291 + omeprazole followed by AZD9291 alone, with a washout period in between.

    Procedure: Pharmacokinetic sampling - AZD9291 · Drug: AZD9291 tablet dosing · Drug: Omeprazole tablet dosing · Procedure: Pharmacokinetic sampling - AZ5140 and AZ7550

Interventions

  • ProcedurePharmacokinetic sampling - AZD9291

    Blood sampling to measure AZD9291

  • AZD9291 80mg tablet taken on Day 5 in Period 1 and Day 1 in Period 2.

  • DrugOmeprazole tablet dosing

    Omeprzole taken from Days 1 to 5 in Period 1.

  • ProcedurePharmacokinetic sampling - AZ5140 and AZ7550

    Blood samples to measure levels of AZ5140 and AZ7550

06

What researchers measure

Primary outcomes

  1. AUC of AZD9291

    Area under the plasma concentration-time curve from zero to infinity for AZD9291

    Time frame: PK samples collected in both period 1 and 2 at pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, and 504 hours post AZD9291 dose

  2. Cmax of AZD9291

    Rate and extent of absorption of AZD9291 following single oral doses of AZD9291 tablet formulation by assessment of maximum plasma concentration (Cmax).

    Time frame: PK samples collected in both period 1 and 2 at pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, and 504 hours post AZD9291 dose.

Secondary outcomes

  1. AUC(0-t)

    Assessment of the PK of AZD9291 (parent compound), AZ5104 (metabolite) and AZ7550 (metabolite) using area under the plasma concentration curve from zero extrapolated to o the time of the last quantifiable concentration, AUC(0-t)

    Time frame: PK samples collected in both period 1 and 2 at pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, and 504 hours post AZD9291 dose.

  2. AUC(0-72)

    Assessment of the PK of AZD9291 (parent compound), AZ5104 (metabolite) and AZ7550 (metabolite) using area under the plasma concentration curve from time zero to 72 hours, AUC(0-72)

    Time frame: PK samples collected in both period 1 and 2 at pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72 hours post AZD9291 dose.

  3. Tmax

    Assessment of the PK of AZD9291 (parent compound), AZ5104 (metabolite) and AZ7550 (metabolite) using time to reach maximum plasma concentration, tmax

    Time frame: PK samples collected in both period 1 and 2 at pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, and 504 hours post AZD9291 dose.

  4. Tlag

    Assessment of the PK of AZD9291 (parent compound), AZ5104 (metabolite) and AZ7550 (metabolite) using lag time before observation of quantifiable analyte concentrations in plasma, tlag

    Time frame: PK samples collected in both period 1 and 2 at pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, and 504 hours post AZD9291 dose.

  5. t(1/2)

    Assessment of the PK of AZD9291 (parent compound), AZ5104 (metabolite) and AZ7550 (metabolite) using the terminal half-life, t(1/2)

    Time frame: PK samples collected in both period 1 and 2 at pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, and 504 hours post AZD9291 dose.

  6. λz

    Assessment of the PK of AZD9291 (parent compound), AZ5104 (metabolite) and AZ7550 (metabolite) using the terminal rate constant, λz

    Time frame: PK samples collected in both period 1 and 2 at pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, and 504 hours post AZD9291 dose.

  7. CL/F of AZD9291

    Assessment of the PK of AZD9291 using the apparent plasma clearance, CL/F

    Time frame: PK samples collected in both period 1 and 2 at pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, and 504 hours post AZD9291 dose.

  8. Vz/F of AZD9291

    Assessment of the PK of AZD9291 using the apparent volume of distribution, Vz/F

    Time frame: PK samples collected in both period 1 and 2 at pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, and 504 hours post AZD9291 dose.

  9. Cmax of AZ5104 and AZ7550

    Assessment of the PK of AZ5104 and AZ7550 (metabolites to AZD9291) using the maximum plasma concentration, Cmax

    Time frame: PK samples collected in both period 1 and 2 at pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, and 504 hours post AZD9291 dose.

  10. AUC of AZ5104 and AZ7550

    Area under the plasma concentration-time curve from zero to infinity of AZ5104 and AZ7550 (metabolites to AZD9291)

    Time frame: PK samples collected in both period 1 and 2 at pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, and 504 hours post AZD9291 dose.

  11. Parent to Metabolite Ratios of AZ5104 and AZ7550 Cmax

    Assessment of the PK of AZ5104 and AZ7550 Cmax using the parent (AZD9291) to metabolite ratios

    Time frame: PK samples collected in both period 1 and 2 at pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, and 504 hours post AZD9291 dose.

  12. Parent to Metabolite Ratios of AZ5104 and AZ7550 AUC

    Assessment of the PK of AZ5104 and AZ7550 AUC using the parent (AZD9291) to metabolite ratios

    Time frame: PK samples collected in both period 1 and 2 at pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, and 504 hours post AZD9291 dose.

07

Results

Posted Dec 31, 2015

Participant flow

First subject enrolled: 3 September 2014 Last Subject Last Visit: 5 January 2015 Study was performed at 2 sites in the USA.

AZD9291 and Omeprazole Co-administration
Participant flow — AZD9291 and Omeprazole Co-administration
MilestoneAZD9291 and Omeprazole
Started68
Completed47
Not completed21
Withdrew: Exceeding pk limits after period 111
Withdrew: Protocol violation4
Withdrew: Adverse event3
Withdrew: Withdrawal by subject1
Withdrew: Protocol non-compliance2
AZD9291 Alone
Participant flow — AZD9291 Alone
MilestoneAZD9291 and Omeprazole
Started47
Completed47
Not completed0

Outcome measures

PrimaryAUC of AZD9291

Area under the plasma concentration-time curve from zero to infinity for AZD9291

Time frame:
PK samples collected in both period 1 and 2 at pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, and 504 hours post AZD9291 dose
Reported as:
Geometric mean · nM.h
AUC of AZD9291
nM.hAZD9291 and Omeprazole Co-administrationAZD9291 Alone
AUC of AZD92916690 ± 28.86269 ± 37.0
Statistical analysis
  • AZD9291 and Omeprazole Co-administration vs AZD9291 Alone · Geometric mean ratio: 106.66 · 90% CI 100.26 to 113.46AZD9291+omeprazole / AZD9291 alone
PrimaryCmax of AZD9291

Rate and extent of absorption of AZD9291 following single oral doses of AZD9291 tablet formulation by assessment of maximum plasma concentration (Cmax).

Time frame:
PK samples collected in both period 1 and 2 at pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, and 504 hours post AZD9291 dose.
Reported as:
Geometric mean · nM
Cmax of AZD9291
nMAZD9291 and Omeprazole Co-administrationAZD9291 Alone
Cmax of AZD9291127.8 ± 26.9126.1 ± 31.0
Statistical analysis
  • AZD9291 and Omeprazole Co-administration vs AZD9291 Alone · Geometric mean ratio: 101.65 · 90% CI 94.65 to 109.16AZD9291+omeprazole / AZD9291 alone
SecondaryAUC(0-t)

Assessment of the PK of AZD9291 (parent compound), AZ5104 (metabolite) and AZ7550 (metabolite) using area under the plasma concentration curve from zero extrapolated to o the time of the last quantifiable concentration, AUC(0-t)

Time frame:
PK samples collected in both period 1 and 2 at pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, and 504 hours post AZD9291 dose.
Reported as:
Geometric mean · nM.h
AUC(0-t)
nM.hAZD9291 and Omeprazole Co-administrationAZD9291 Alone
AZD92916673 (2340 to 10200)6249 (2660 to 14100)
AZ5104546.5 (226 to 939)539.2 (230 to 1110)
AZ7550520.0 (208 to 1010)560.0 (300 to 942)
SecondaryAUC(0-72)

Assessment of the PK of AZD9291 (parent compound), AZ5104 (metabolite) and AZ7550 (metabolite) using area under the plasma concentration curve from time zero to 72 hours, AUC(0-72)

Time frame:
PK samples collected in both period 1 and 2 at pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72 hours post AZD9291 dose.
Reported as:
Geometric mean · nM.h
AUC(0-72)
nM.hAZD9291 and Omeprazole Co-administrationAZD9291 Alone
AZD92914404 (1710 to 6410)4106 (1760 to 7530)
AZ5104301.5 (151 to 589)304.0 (153 to 540)
AZ7550216.5 (82.1 to 398)231.3 (100 to 445)
SecondaryTmax

Assessment of the PK of AZD9291 (parent compound), AZ5104 (metabolite) and AZ7550 (metabolite) using time to reach maximum plasma concentration, tmax

Time frame:
PK samples collected in both period 1 and 2 at pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, and 504 hours post AZD9291 dose.
Reported as:
Median · h
Tmax
hAZD9291 and Omeprazole Co-administrationAZD9291 Alone
AZD92916 (5 to 48.08)6 (3 to 12.1)
AZ51048 (5 to 72.12)7 (4 to 48.05)
AZ755010 (5 to 72.42)10 (5 to 71.77)
SecondaryTlag

Assessment of the PK of AZD9291 (parent compound), AZ5104 (metabolite) and AZ7550 (metabolite) using lag time before observation of quantifiable analyte concentrations in plasma, tlag

Time frame:
PK samples collected in both period 1 and 2 at pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, and 504 hours post AZD9291 dose.
Reported as:
Median · h
Tlag
hAZD9291 and Omeprazole Co-administrationAZD9291 Alone
AZD92910.00 (0.00 to 0.00)0.00 (0.00 to 0.00)
AZ51040.00 (0.00 to 2.00)0.00 (0.00 to 1.00)
AZ75500.00 (0.00 to 2.00)0.00 (0.00 to 1.00)
Secondaryt(1/2)

Assessment of the PK of AZD9291 (parent compound), AZ5104 (metabolite) and AZ7550 (metabolite) using the terminal half-life, t(1/2)

Time frame:
PK samples collected in both period 1 and 2 at pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, and 504 hours post AZD9291 dose.
Reported as:
Geometric mean · h
t(1/2)
hAZD9291 and Omeprazole Co-administrationAZD9291 Alone
AZD929158.99 (39.2 to 77.1)63.60 (52.3 to 80.4)
AZ510451.06 (31.1 to 85.4)54.47 (34.5 to 87.7)
AZ755071.34 (47.0 to 106)72.16 (48.5 to 102)
Secondaryλz

Assessment of the PK of AZD9291 (parent compound), AZ5104 (metabolite) and AZ7550 (metabolite) using the terminal rate constant, λz

Time frame:
PK samples collected in both period 1 and 2 at pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, and 504 hours post AZD9291 dose.
Reported as:
Geometric mean · 1/h
λz
1/hAZD9291 and Omeprazole Co-administrationAZD9291 Alone
AZD92910.011748 (0.00899 to 0.0177)0.010898 (0.00862 to 0.0132)
AZ51040.013577 (0.00812 to 0.0223)0.012722 (0.00790 to 0.0201)
AZ75500.009718 (0.00656 to 0.0147)0.009606 (0.00677 to 0.0143)
SecondaryCL/F of AZD9291

Assessment of the PK of AZD9291 using the apparent plasma clearance, CL/F

Time frame:
PK samples collected in both period 1 and 2 at pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, and 504 hours post AZD9291 dose.
Reported as:
Geometric mean · L/h
CL/F of AZD9291
L/hAZD9291 and Omeprazole Co-administrationAZD9291 Alone
CL/F of AZD929123.93 (15.6 to 68.4)25.55 (11.3 to 60.1)
SecondaryVz/F of AZD9291

Assessment of the PK of AZD9291 using the apparent volume of distribution, Vz/F

Time frame:
PK samples collected in both period 1 and 2 at pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, and 504 hours post AZD9291 dose.
Reported as:
Geometric mean · L
Vz/F of AZD9291
LAZD9291 and Omeprazole Co-administrationAZD9291 Alone
Vz/F of AZD92912037 (1280 to 3870)2343 (1250 to 5120)
SecondaryCmax of AZ5104 and AZ7550

Assessment of the PK of AZ5104 and AZ7550 (metabolites to AZD9291) using the maximum plasma concentration, Cmax

Time frame:
PK samples collected in both period 1 and 2 at pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, and 504 hours post AZD9291 dose.
Reported as:
Geometric mean · nM
Cmax of AZ5104 and AZ7550
nMAZD9291 and Omeprazole Co-administrationAZD9291 Alone
AZ51045.543 ± 26.95.889 ± 31.0
AZ75503.913 (1.68 to 7.98)4.402 (2.04 to 9.69)
Statistical analysis
  • AZD9291 and Omeprazole Co-administration vs AZD9291 Alone · Geometric mean ratio: 94.79 · 90% CI 88.77 to 101.21
  • AZD9291 and Omeprazole Co-administration vs AZD9291 Alone · Geomteric mean ratio: 89.70 · 90% CI 83.89 to 95.91
SecondaryAUC of AZ5104 and AZ7550

Area under the plasma concentration-time curve from zero to infinity of AZ5104 and AZ7550 (metabolites to AZD9291)

Time frame:
PK samples collected in both period 1 and 2 at pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, and 504 hours post AZD9291 dose.
Reported as:
Geometric mean · nM.h
AUC of AZ5104 and AZ7550
nM.hAZD9291 and Omeprazole Co-administrationAZD9291 Alone
AZ5104556.6 ± 28.8550.7 ± 37.0
AZ7750536.5 (231 to 1020)574.9 (309 to 955)
Statistical analysis
  • AZD9291 and Omeprazole Co-administration vs AZD9291 Alone · Geometric mean ratio: 102.32 · 90% CI 96.87 to 108.07AZD9291+omeprazole / AZD9291 alone
  • AZD9291 and Omeprazole Co-administration vs AZD9291 Alone · Geometric mean ratio: 94.03 · 90% CI 89.92 to 98.33
SecondaryParent to Metabolite Ratios of AZ5104 and AZ7550 Cmax

Assessment of the PK of AZ5104 and AZ7550 Cmax using the parent (AZD9291) to metabolite ratios

Time frame:
PK samples collected in both period 1 and 2 at pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, and 504 hours post AZD9291 dose.
Reported as:
Geometric mean · Ratio
Parent to Metabolite Ratios of AZ5104 and AZ7550 Cmax
RatioAZD9291 and Omeprazole Co-administrationAZD9291 Alone
AZ51040.04335 (0.0255 to 0.0873)0.04671 (0.0293 to 0.0908)
AZ75500.03061 (0.0169 to 0.0530)0.03491 (0.0169 to 0.0708)
SecondaryParent to Metabolite Ratios of AZ5104 and AZ7550 AUC

Assessment of the PK of AZ5104 and AZ7550 AUC using the parent (AZD9291) to metabolite ratios

Time frame:
PK samples collected in both period 1 and 2 at pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, and 504 hours post AZD9291 dose.
Reported as:
Geometric mean · Ratio
Parent to Metabolite Ratios of AZ5104 and AZ7550 AUC
RatioAZD9291 and Omeprazole Co-administrationAZD9291 Alone
AZ51040.08318 (0.0464 to 0.137)0.08785 (0.0587 to 0.133)
AZ75500.08019 (0.0334 to 0.152)0.09166 (0.0424 to 0.207)

Adverse events

Collected over AEs collected from the day prior to first dose of treatment (omeprazole) until the follow up visit, approximately 3 months.. Non-serious events are listed at a 4% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AZD9291 and Omeprazole Co-administration—3/68 (4.4%)8/68 (11.8%)
AZD9291 Alone—0/47 (0%)2/47 (4.3%)
Most frequent serious events
Most frequent serious events
EventAZD9291 and Omeprazole Co-administrationAZD9291 Alone
Transaminases increasedInvestigations2/680/47
CholelithiasisHepatobiliary disorders1/680/47
Blood creatine phosphokinase increasedInvestigations1/680/47
Most frequent other events
Most frequent other events
EventAZD9291 and Omeprazole Co-administrationAZD9291 Alone
HeadacheNervous system disorders5/680/47
Blood creatine phosphokinase increasedInvestigations3/682/47

Baseline characteristics

Age, Continuous
Age, Continuous(Years)AZD9291 and Omeprazole
Mean34.0 ± 11.08
Sex: Female, Male
Sex: Female, Male(Participants)AZD9291 and Omeprazole
Female0
Male68
08

Study locations

2 sites
  • Research Site
    Overland Park, Kansas, United States
  • Research Site
    Minneapolis, Minnesota, United States
09

References and documents

Publications

  • Vishwanathan K, Dickinson PA, Bui K, Cassier PA, Greystoke A, Lisbon E, Moreno V, So K, Thomas K, Weilert D, Yap TA, Plummer R. The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients With Non-Small-Cell Lung Cancer and in Healthy Volunteers. J Clin Pharmacol. 2018 Apr;58(4):474-484. doi: 10.1002/jcph.1035. Epub 2017 Nov 26. PubMed 29178442 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2014, a primary completion of Jan 2015 and a completion of Jan 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2015, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2014
First posted
Aug 25, 2014
Start
Sep 2014
Primary completionActual
Jan 2015
CompletionActual
Jan 2015
Results first posted
Dec 31, 2015
Last update
Jun 24, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02224053
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Aug 25, 2014
Start date
Sep 2014
Primary completion
Jan 2015
Completion
Jan 2015
Results posted
Dec 31, 2015
Last update
Jun 24, 2016

Study contacts

Serban Ghiorghiu, MSD
study director · AstraZeneca

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Osimertinib

Start the discussion